Profound Medical Corp.
PROF
Rank in Stocks
#15696
Profound Medical Corp., along with its subsidiaries, operates as a... Profound Medical Corp., along with its subsidiaries, operates as a commercial-stage medical technology firm. The company specializes in creating magnetic resonance (MR) guided ablation therapies designed to address prostate conditions, uterine fibroids, and to provide palliative pain management. Its market reach extends to Canada, Germany, the United States, and Finland. The company's primary offering is the TULSA-PRO system, which is engineered to integrate with magnetic resonance imaging (MRI) scanners within hospitals and clinical treatment facilities. Additionally, Profound Medical offers Sonalleve, a versatile therapeutic platform that treats uterine fibroids, delivers palliative pain relief for bone metastases, and provides non-invasive solutions for uterine fibroid treatment. Profound Medical Corp. maintains its corporate headquarters in Mississauga, Canada.
Share Price
$6.38
Last synced: 2026-11-20
Market Cap
$235.45M
Change (1 day)
-3.19%
Change (1 year)
6.16%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Profound Medical Corp. (PROF)
Category
Healthcare
P/S ratio for Profound Medical Corp. (PROF)
P/S ratio as of November 2026 TTM: 11.54
According to Profound Medical Corp.'s latest financial reports and stock price, its current price-to-sales ratio (TTM) is 11.54. At the end of 2025 the company had a P/S ratio of 14.48.
P/S ratio history for Profound Medical Corp. from 2014 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 11.54 | -20.28% |
| 2025 | 14.48 | -42.21% |
| 2024 | 25.05 | -23.31% |
| 2023 | 32.66 | -27.46% |
| 2022 | 45.03 | 6.05% |
| 2021 | 42.46 | -31.53% |
| 2020 | 62.01 | 60.35% |
| 2019 | 38.67 | 33.81% |
| 2018 | 28.90 | 83.57% |
| 2017 | 15.74 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 3.90 | -66.24% |
US
|
|
| 3.50 | -69.64% |
IE
|
|
| 4.48 | -61.17% |
US
|
|
| 3.05 | -73.58% |
US
|
|
| 9.23 | -20.04% |
US
|
Questions about Profound Medical Corp.'s P/S ratio
What is Profound Medical Corp.'s P/S ratio?
Profound Medical Corp.'s P/S ratio is 11.54, as of Nov 2026.
What was Profound Medical Corp.'s P/S ratio in 2025?
In 2025, Profound Medical Corp.'s P/S ratio was 14.48, compared with 25.05 in 2024.
How has Profound Medical Corp.'s P/S ratio changed since 2020?
From 2020 to 2025, Profound Medical Corp.'s P/S ratio was highest in 2020 (62.01) and lowest in 2025 (14.48).
How does Profound Medical Corp.'s P/S ratio compare with similar companies?
Profound Medical Corp.'s P/S ratio (11.54) is higher than that of all 5 similar companies listed above. The highest among them is Edwards Lifesciences Corporation, with 9.23.